Company Filing History:
Years Active: 2022-2024
Title: Morten Lind Jensen: Innovator in Diabetes Management
Introduction
Morten Lind Jensen is a notable inventor based in Copenhagen, Denmark. He has made significant contributions to the field of diabetes management through his innovative patents. With a total of 2 patents, Jensen's work focuses on improving insulin dosage adjustments for individuals with diabetes.
Latest Patents
One of Morten Lind Jensen's latest patents is titled "Basal titration with adaptive target glucose level." This patent outlines systems and methods for adjusting long-acting insulin medicament dosages for a subject. The process involves obtaining a plurality of timestamped glucose measurements from the subject. A titration glucose level is computed as a measure of central tendency of a subset of small glucose measurements identified within the timestamped data. This measure represents small glucose measurements for a primary time window, allowing for the adjustment or maintenance of long-acting insulin dosages based on the obtained titration glucose level.
Career Highlights
Morten Lind Jensen is currently associated with Novo Nordisk A/S, a leading global healthcare company specializing in diabetes care. His work at Novo Nordisk has been instrumental in developing innovative solutions for diabetes management, enhancing the quality of life for patients.
Collaborations
Jensen has collaborated with several talented individuals in his field, including Tinna Bjoerk Aradottir and Henrik Bengtsson. These collaborations have contributed to the advancement of research and development in diabetes care.
Conclusion
Morten Lind Jensen's contributions to diabetes management through his innovative patents highlight his commitment to improving patient care. His work continues to influence the field and offers promising advancements for individuals living with diabetes.